Core Viewpoint - Harbin Sanlian Pharmaceutical (002900.SZ) has announced its first annual loss since its A-share listing in 2017, with a projected revenue of 790 million yuan for 2025, a decrease of 30% year-on-year, and a net loss estimated between 315 million to 375 million yuan [2][4]. Revenue and Profitability - The company's revenue is expected to drop by 343 million yuan compared to the previous year, primarily due to a significant decline in sales prices and rigid costs [2][4]. - The basic earnings per share are projected to be between -1.19 and -1 yuan [2][4]. - The net profit attributable to shareholders is forecasted to be -375 million yuan, marking a 739.11% decline year-on-year [4]. Price Pressure and Market Competition - A major factor in the company's poor performance is the decline in sales prices, particularly due to the implementation of centralized drug procurement policies, which have severely impacted the prices of core products [3][4]. - The product "Injection of Yanhuning" is facing an average price drop of 86% due to competitive pressures from 31 companies participating in the procurement [5][6]. - The "Ondansetron Hydrochloride Injection" has seen a price reduction of 56.85% after entering the procurement process, leading to a 37.91% decline in revenue despite increased sales volume [8]. Asset Impairment and Expenses - The company has faced significant asset impairments, with a total of 59.49 million yuan in impairment provisions impacting net profit by over 55 million yuan [11][12]. - Inventory write-downs, particularly for "Injection of Yanhuning," have resulted in a reduction of over 87% in recoverable amounts, contributing to the overall financial strain [11][12]. - High fixed expenses have not decreased in line with revenue, leading to increased expense ratios [13]. Strategic Moves and Future Outlook - In response to the challenges, the company is attempting to pivot towards a health-oriented business model, including the establishment of a new division focused on synthetic biology and the launch of new beauty products [14][18]. - However, the beauty industry is highly competitive, and the synthetic biology sector requires significant investment and long development cycles, posing additional challenges for the company [18].

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. reported a decline in both revenue and net profit for the first half of 2025, continuing a trend of decreasing performance that began last year [2][3] Financial Performance - In the first half of 2025, the company achieved revenue of approximately 413 million yuan, a year-on-year decrease of 21.08% [2] - The net profit attributable to shareholders was a loss of approximately 92.39 million yuan, a year-on-year decrease of 451.68% [2] - For the full year of 2024, the company reported revenue of 1.132 billion yuan, down 4.58% year-on-year, and a net profit of 58.68 million yuan, down 20.35% year-on-year [4][5] Core Business Segment - The pharmaceutical segment, which is the core business, faced significant revenue pressure, generating sales of 356 million yuan in the first half of 2025, a decline of 24.25% year-on-year, accounting for 86.08% of total revenue [3][4] - Revenue from infusion products was 132 million yuan, down 12.14% year-on-year [4] - Non-infusion products saw growth in sales due to successful bidding in centralized procurement, but the revenue from small-volume injectables dropped by 37.91% due to a 56.85% price reduction on a key product [4] New Business Segments - The animal health and wellness sectors, which the company has been focusing on, have not yet become significant contributors to revenue and are still in the investment phase [6] - Revenue from functional foods, cosmetics, veterinary drugs, and feed additives accounted for only 7.21% of total revenue in 2024 [7] Subsidiary Performance - The company’s two wholly-owned subsidiaries, Lanxi Pharmaceutical and Lingbao Sanlian, contributed to the overall losses [8] - Lanxi Pharmaceutical reduced sales to the parent company due to previous stockpiling of raw materials, leading to a significant drop in revenue [8] - Lingbao Sanlian, in its initial phase, reported negative profit margins and increased depreciation costs after reaching operational status [8]